logo-loader
viewArecor

Arecor's Sarah Howell discusses results from successful phase I insulin trial

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Andrew Scott following the successful completion of the phase I trial for its ultra-rapid acting insulin for diabetics.

She says the product was shown to have a favourable profile when compared with standard treatments and the complete results have been submitted for publication at a big diabetes conference next year.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tonix Pharmaceuticals CEO talks through recent pre-clinical and clinical...

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Seth Lederman sat down with Proactive at the BIO CEO & investor Conference in New York. Lederman says the biopharma company had recently unveiled the pre-clinical results of TNX-801, its live virus horsepox vaccine that prevents...

4 hours, 13 minutes ago

2 min read